Avoiding PXR and CAR activation and CYP3A4 enzyme induction

Topics in Medicinal Chemistry

Volumn 9, Issue , 2014, Pages 159-190

  Sinz, Michael W ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Constitutive androstane receptor; CYP3A4; Drug discovery; Drugdrug interactions; Pregnane X receptor; Structure activity relationship

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR; ARMODAFINIL; AROMATIC HYDROCARBON RECEPTOR; AVASIMIBE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLOBAZAM; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 3A4; DESVENLAFAXINE; ECHINACEA EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLYCYRRHIZIC ACID; HYPERFORIN; LERSIVIRINE; MESSENGER RNA; MIDAZOLAM; MITOTANE; NEVIRAPINE; OXIDOREDUCTASE INHIBITOR; PHENYTOIN; PLECONARIL; PREGNANE X RECEPTOR; QUERCETIN; RIFAMPICIN; SALVIA MILTIORRHIZA EXTRACT; SONIC HEDGEHOG PROTEIN; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; DRUG INTERACTION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; LIGAND BINDING; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION;

EID: 84916240822     PISSN: 18622461     EISSN: 1862247X     Source Type: Book Series    
DOI: 10.1007/7355_2013_24     Document Type: Article

References (81)

1. Huang SM, Lesko LJ (2004) Drug–drug, drug–dietary supplement, and drug–citrus fruit and other food interactions: what have we learned? J Clin Pharmacol 44:559–569
2. Huang SM, Strong JM, Zhang L et al (2008) New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662–670
3. Muirhead GJ, Wulff MB, Fielding A et al (2000) Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 50:99–107
4. Obach RS, Ryder TF (2010) Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos 38:1381–1391
5. Backman JT, Olkkola KT, Neuvonen PJ (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59:7–13
6. Backman JT, Olkkola KT, Ojala M et al (1996) Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 37:253–257
7. Ma JD, Nafziger AN, Rhodes G et al (2006) Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam. Drug Metab Dispos 34:783–785
8. Levy R (2012) Metabolism and transport drug–drug interaction database, 2005–2012 edn. University of Washington, Washington
9. Chang TK (2009) Activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) by herbal medicines. AAPS J 11:590–601
10. Choi SY, Koh KH, Jeong H (2013) Isoform-specific regulation of cytochromes p450 expression by estradiol and progesterone. Drug Metab Dispos 41:263–269
11. Jeong H, Choi S, Song JW et al (2008) Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica 38:62–75
12. Bertilsson L, Hojer B, Tybring G et al (1980) Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther 27:83–88
13. Simonsson US, Jansson B, Hai TN et al (2003) Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin Pharmacol Ther 74:32–43
14. Wilkinson GR (2001) Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Hardman J, Limbird L, Goodman Gilman A (eds) The pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York
15. Ema (2012) Guideline on the investigation of drug interactions. Guideline on the investigation of drug interactions [Online]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf Accessed September 2012
16. FDA (2012) Guidance for industry: drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. Guidance for industry: drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations [Online]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM292362.pdf
17. Kumar S, Sharma R, Roychowdhury A (2012) Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective. Curr Med Chem 19:3605–3621
18. Pascussi JM, Drocourt L, Gerbal-Chaloin S et al (2001) Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 268:6346–6358
19. Li L, Sinz MW, Zimmermann K et al (2012) An insulin-like growth factor 1 receptor inhibitor induces CYP3A4 expression through a pregnane X receptor-independent, noncanonical constitutive androstane receptor-related mechanism. J Pharmacol Exp Ther 340:688–697
20. Gonzalez FJ (2007) The 2006 Bernard B. Brodie Award Lecture. Cyp2e1. Drug Metab Dispos 35:1–8
21. Timsit YE, Negishi M (2007) CAR and PXR: the xenobiotic-sensing receptors. Steroids 72:231–246
22. Shukla SJ, Nguyen DT, Macarthur R et al (2009) Identification of pregnane X receptor ligands using time-resolved fluorescence resonance energy transfer and quantitative high-throughput screening. Assay Drug Dev Technol 7:143–169
23. Shukla SJ, Sakamuru S, Huang R et al (2011) Identification of clinically used drugs that activate pregnane X receptors. Drug Metab Dispos 39:151–159
24. Sinz M, Kim S, Zhu Z et al (2006) Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 7:375–388
25. Di Masi A, De Marinis E, Ascenzi P et al (2009) Nuclear receptors CAR and PXR: molecular, functional, and biomedical aspects. Mol Aspects Med 30:297–343
26. Poso A, Honkakoski P (2006) Ligand recognition by drug-activated nuclear receptors PXR and CAR: structural, site-directed mutagenesis and molecular modeling studies. Mini Rev Med Chem 6:937–947
27. Jones SA, Moore LB, Shenk JL et al (2000) The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14:27–39
28. Kim S, Dinchuk JE, Anthony MN et al (2010) Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction. Drug Metab Dispos 38:16–24
29. Kliewer SA, Goodwin B, Willson TM (2002) The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 23:687–702
30. Nishimura M, Koeda A, Suganuma Y et al (2007) Comparison of inducibility of CYP1A and CYP3A mRNAs by prototypical inducers in primary cultures of human, cynomolgus monkey, and rat hepatocytes. Drug Metab Pharmacokinet 22:178–186
31. Prueksaritanont T, Kuo Y, Tang C et al (2006) In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. Drug Metab Dispos 34:1546–1555
32. Carnahan VE, Redinbo MR (2005) Structure and function of the human nuclear xenobiotic receptor PXR. Curr Drug Metab 6:357–367
33. Chen T (2008) Nuclear receptor drug discovery. Curr Opin Chem Biol 12:418–426
34. Chen Y, Tang Y, Robbins GT et al (2010) Camptothecin attenuates cytochrome P450. 3A4 induction by blocking the activation of human pregnane X receptor. J Pharmacol Exp Ther 334:999–1008
35. Huang H, Wang H, Sinz M et al (2007) Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 26:258–268
36. Lim YP, Ma CY, Liu CL et al (2012) Sesamin: a naturally occurring lignan inhibits CYP3A4 by antagonizing the pregnane X receptor activation. Evid Based Complement Alternat Med 2012:242810
37. Mcginnity DF, Zhang G, Kenny JR et al (2009) Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab Dispos 37:1259–1268
38. Raucy JL, Lasker JM (2010) Current in vitro high throughput screening approaches to assess nuclear receptor activation. Curr Drug Metab 11:806–814
39. Sinz M, Wallace G, Sahi J (2008) Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. AAPS J 10:391–400
40. Zhu Z, Kim S, Chen T et al (2004) Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays. J Biomol Screen 9:533–540
41. Zhu Z, Puglisi J, Connors D et al (2007) Use of cryopreserved transiently transfected cells in high-throughput pregnane X receptor transactivation assay. J Biomol Screen 12:248–254
42. Cui X, Thomas A, Gerlach V et al (2008) Application and interpretation of hPXR screening data: Validation of reporter signal requirements for prediction of clinically relevant CYP3A4 inducers. Biochem Pharmacol 76:680–689
43. El-Sankary W, Gibson GG, Ayrton A et al (2001) Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos 29:1499–1504
44. Chu V, Einolf HJ, Evers R et al (2009) In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of America perspective. Drug Metab Dispos 37:1339–1354
45. Fahmi OA, Ripp SL (2010) Evaluation of models for predicting drug–drug interactions due to induction. Expert Opin Drug Metab Toxicol 6:1399–1416
46. Hewitt NJ, De Kanter R, Lecluyse E (2007) Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry–do they comply with FDA recommendations? Chem Biol Interact 168:51–65
47. Sinz M, Kim S (2006) Stem cells, immortalized cells, and primary cells in ADMET assays. Drug Discov Today Technol 3:79–85
48. Hasegawa M, Kapelyukh Y, Tahara H et al (2011) Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line. Mol Pharmacol 80:518–528
49. Kim S, Pray D, Zheng M et al (2008) Quantitative relationship between rifampicin exposure and induction of Cyp3a11 in SXR humanized mice: extrapolation to human CYP3A4 induction potential. Drug Metab Lett 2:169–175
50. Gao YD, Olson SH, Balkovec JM et al (2007) Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach. Xenobiotica 37:124–138
51. Schuster D, Langer T (2005) The identification of ligand features essential for PXR activation by pharmacophore modeling. J Chem Inf Model 45:431–439
52. Schlegel KA, Yang ZQ, Reger TS et al (2010) Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists. Bioorg Med Chem Lett 20: 5147–5152
53. Harper S, Avolio S, Pacini B et al (2005) Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase. J Med Chem 48:4547–4557
54. Fotsch C, Bartberger MD, Bercot EA et al (2008) Further studies with the 2-amino-1,3-thiazol- 4(5H)-one class of 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: reducing pregnane X receptor activity and exploring activity in a monkey pharmacodynamic model. J Med Chem 51:7953–7967
55. Rew Y, Mcminn DL, Wang Z et al (2009) Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11beta-HSD1 inhibitors. Bioorg Med Chem Lett 19:1797–1801
56. Kaizerman JA, Aaron W, An S et al (2010) Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines. Bioorg Med Chem Lett 20: 4607–4610
57. Zimmermann K, Wittman MD, Saulnier MG et al (2010) SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors. Bioorg Med Chem Lett 20:1744–1748
58. Khandelwal A, Krasowski MD, Reschly EJ et al (2008) Machine learning methods and docking for predicting human pregnane X receptor activation. Chem Res Toxicol 21: 1457–1467
59. Wipf P, Gong H, Janjic JM et al (2007) New opportunities for pregnane X receptor (PXR) targeting in drug development. lessons from Enantio- and species-specific PXR ligands identified from a discovery library of amino acid analogues. Mini Rev Med Chem 7:617–625
60. Wang H, Lecluyse EL (2003) Role of orphan nuclear receptors in the regulation of drugmetabolising enzymes. Clin Pharmacokinet 42:1331–1357
61. Lynch C, Pan Y, Li L et al (2012) Identification of novel activators of constitutive androstane receptor from FDA-approved drugs by integrated computational and biological approaches. Pharm Res 30:489–501
62. Zhou X, Xu H (2009) Structure and function of PXR and CAR. In: XieW(ed) Nuclear receptors in drug metabolism. Wiley, Hoboken
63. Xu RX, Lambert MH, Wisely BB et al (2004) A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer. Mol Cell 16:919–928
64. Kachaylo EM, Pustylnyak VO, Lyakhovich VV et al (2011) Constitutive androstane receptor (CAR) is a xenosensor and target for therapy. Biochemistry (Mosc) 76:1087–1097
65. Anderson LE, Dring AM, Hamel LD et al (2011) Modulation of constitutive androstane receptor (CAR) and pregnane X receptor (PXR) by 6-arylpyrrolo[2,1-d][1,5]benzothiazepine derivatives, ligands of peripheral benzodiazepine receptor (PBR). Toxicol Lett 202:148–154
66. Kublbeck J, Jyrkkarinne J, Molnar F et al (2011) New in vitro tools to study human constitutive androstane receptor (CAR) biology: discovery and comparison of human CAR inverse agonists. Mol Pharm 8:2424–2433
67. Faucette SR, Zhang TC, Moore R et al (2007) Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 320:72–80
68. Kanno Y, Inouye Y (2010) A consecutive three alanine residue insertion mutant of human CAR: a novel CAR ligand screening system in HepG2 cells. J Toxicol Sci 35:515–525
69. Kublbeck J, Laitinen T, Jyrkkarinne J et al (2011) Use of comprehensive screening methods to detect selective human CAR activators. Biochem Pharmacol 82:1994–2007
70. Pascussi JM, Gerbal-Chaloin S, Duret C et al (2008) The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol 48:1–32
71. Li H, Chen T, Cottrell J et al (2009) Nuclear translocation of adenoviral-enhanced yellow fluorescent protein-tagged-human constitutive androstane receptor (hCAR): a novel tool for screening hCAR activators in human primary hepatocytes. Drug Metab Dispos 37:1098–1106
72. Wu B, Li S, Dong D (2013) 3D structure and ligand specificity of nuclear xenobiotic receptors CAR, PXR and VDR. Drug Discov Today 18:574–581
73. Pustylnyak V, Yarushkin A, Kachaylo E et al (2011) Effect of several analogs of 2,4,6- triphenyldioxane-1,3 on constitutive androstane receptor activation. Chem Biol Interact 192: 177–183
74. Repo S, Jyrkkarinne J, Pulkkinen JT et al (2008) Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis. J Med Chem 51:7119–7131
75. Dring AM, Anderson LE, Qamar S et al (2010) Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. Chem Biol Interact 188:512–525
76. Kublbeck J, Jyrkkarinne J, Poso A et al (2008) Discovery of substituted sulfonamides and thiazolidin-4-one derivatives as agonists of human constitutive androstane receptor. Biochem Pharmacol 76:1288–1297
77. Jyrkkarinne J, Windshugel B, Ronkko T et al (2008) Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship. J Med Chem 51:7181–7192
78. Kohle C, Bock KW (2009) Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem Pharmacol 77:689–699
79. Li H, Wang H (2010) Activation of xenobiotic receptors: driving into the nucleus. Expert Opin Drug Metab Toxicol 6:409–426
80. Pavek P, Dvorak Z (2008) Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab 9:129–143
81. Tolson AH, Wang H (2010) Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev 62:1238–1249